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Department, Hospital-Clinic-IDIBAPS, Barcelona, SpainAbstractThe management of multidrug-resistant human immunodeﬁciency virus (MDR HIV) infections in children is particularly challenging due to the
lack of experience with new drugs. Dolutegravir, combined with an optimized antiretroviral background therapy, is promising for the
treatment of MDR HIV and has been approved recently for adults and adolescents. Data for children are extremely limited. We describe
the efﬁcacy, safety and plasmatic levels of a dolutegravir-based, complex active antiretroviral treatment regimen in a severely overweight
11-year-old child infected with an MDR HIV strain.
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E-mail: noemie.wagner@hcuge.chCase reportVertically infected children may have signiﬁcant human immu-
nodeﬁciency virus (HIV) drug resistance due to non-
suppressive regimens and/or inadequate adherence [1]. As a
result of the lack of experience with newer drugs, these cases
are extremely challenging for clinicians. We describe a case of a
successful treatment based on dolutegravir in a patient with
multidrug class resistance.
An 11-year-old boy has been treated at our clinic for a
vertical HIV infection since 2009. Due to either viral failure or
intolerance, he was exposed successively to severalNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artiantiretroviral regimens between 2009 and May 2013, including
zidovudine, stavudine, tenofovir, lamivudine, efavirenz, lopina-
vir/ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir and
raltegravir. Following chronically poor compliance with care
and antiretroviral therapy, he presented multiple virological
failures, resulting in the development of a multidrug-resistant
(MDR) HIV strain (Table 1). The highest viral load was
6.8 × 105 copies/mL (April 2013) and the CD4 nadir was 53
cells/μL (5%) (December 2010). He was also signiﬁcantly
overweight with a weight of 56.5 kg (>90th centile) and a body
mass index of 26.1 kg/m2 (>90th centile).
After a multidisciplinary discussion, the following regimen
was introduced in May 2013: enfuvirtide 90 mg twice a day
subcutaneously; dolutegravir 50 mg once a day; tenofovir 300
mg once a day, emtricitabine 200 mg once a day (co-formulated
as Truvada®, Gilead, Foster City, CA, USA) and abacavir 300
mg twice a day with excellent initial virological and immuno-
logical responses (Fig. 1). However, despite the daily home visit
of a nurse for enfuvirtide injections, adherence to oral treat-
ment was poor, resulting in an increase in viraemia in July 2013.New Microbe and New Infect 2015; 6: 1–4
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TABLE 1. Genotypic drug resistance interpretation according to the French National Agency for AIDS Research (ANRS)
Drug
8 January 2013 11 July 2013
Cumulative genotype (six samples)
29 June 2010 to 11 July 2013
Mutations/Interpretationa Mutations/Interpretationa Mutations/Interpretationa
NRTI Lamivudine/Emtricitabine
(3TC/FTC)
S S 184V R
Abacavir (ABC) S 215Y S 184V, 215Y, 219Q I
Stavudine (D4T) 219Q S 215Y R 215N, 215S, 215Y, 219Q R
Didanosine (DDI) 219Q S 215Y S 184V, 215Y, 219Q I
Tenofovir (TDF) S 215Y S 215Y S
Zidovudine (AZT) 219Q S 215Y R 215N, 215S, 215Y, 219Q R
NNRTI Efavirenz (EFV) 188L, 190S R 188L, 190S R 188L, 190S R
Etravirine (ETR) 98G, 190S S 98G, 179M, 190S I 98G, 179M, 190S I
Nevirapine (NVP) 188L, 190S R 188L, 190S R 188H, 188L, 190S R
Rilpivirine (RPV) 188L R 188L R 188L R
PI Atazanavir (ATV) 10I, 16E, 33F, 46I, 84V R 10I, 16E, 33F, 46I, 84V R 10I, 10V, 16E, 33F, 46I, 84V, 85V R
Darunavir (DRV) 11I, 33F, 76V, 84V R 33F, 76V, 84V I 11I, 33F, 76V, 84V R
Indinavir (IDV) 36I, 46I, 84V R 36I, 46I, 84V R 36I, 46I, 84V R
Lopinavir (LPVr) 10I, 33F, 46I, 76V, 84V R 10I, 33F, 46I, 76V, 84V R 10I, 10V, 33F, 46I, 76V, 84V R
Nelﬁnavir (NFV) 10I, 36I, 46I, 84V R 10I, 36I, 46I, 84V R 10I, 36I, 46I, 84V R
Saquinavir (SQV) 10I, 15V, 20I, 84V R 10I, 15V, 20I, 84V R 10I, 10V, 15V, 20I, 84V R
Tipranavir/(TPV) 36I, 58E, 69K, 89M R 36I, 58E, 69K, 89M R 36I, 58E, 69K, 89M R
Fosamprenavir (FOS) 10I, 10V, 33F, 36I, 84V R 10I, 33F, 36I, 84V R 10I, 10V, 33F, 36I, 84V R
INSTI Dolutegravir (DTG) 74I, 155H S 74I, 155H S 74I, 155H S
Elvitegravir (EVG) 155H R R 155H R
Raltegravir (RAL) 155H R R 155H R
FI Enfuvirtide (T20) S 36D, 38M R 36D, 38M R
HIV-1 strain: X-4 tropic
FI, fusion inhibitor; INSTI, integrase strand transfer inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI,
protease inhibitor.
aInterpretation: S, susceptible; I, intermediate; R, resistant.
2 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNIResistance to enfuvirtide was detected at this time, but the drug
was kept for a potential residual activity and ﬁtness effect [2]. A
directly observed therapeutic strategy was implemented to
improve adherence. However, viraemia remained detectable
(between 30 and 130 copies/mL) during the following 6 months
(Fig. 1), presumably because of insufﬁcient activity of the otherFIG. 1. CD4 cell count and human immunodeﬁciency virus (HIV) viral load
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cision was made to add etravirine 400 mg once a day and
darunavir/ritonavir 600/100 mg twice daily to the regimen.
Etravirine was considered to retain some antiretroviral activity
against the MDR HIV strain, but it is known to decrease
dolutegravir plasma levels [3]. For this reason, ritonavir-evolution during follow up.
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the dolutegravir level [4]. We assumed also a residual activity of
darunavir/ritonavir. Two weeks after this change of therapy,
under a twice-daily regimen of enfuvirtide, abacavir, darunavir/
ritonavir, dolutegravir and once daily tenofovir, emtricitabine
and etravirine, viraemia became undetectable (<20 copies/mL).
Administration of enfuvirtide was stopped 2 months later, and
the patient maintained undetectable levels at the following
viraemia determinations.
Despite the previous exposure to an integrase strand transfer
inhibitor, dolutegravir treatment was ﬁrst started with a dose of
50 mg once a day, because of lack of data in children, and dosage
was adjusted according to plasma levels as a main pharmacoki-
netics parameter. The ﬁrst dolutegravir steady-state plasma level
(1487 ng/mL)—determined 3 h after dosing using liquid chro-
matography combined with mass spectrometry according to a
previously published, modiﬁed method and extrapolated to 24 h
after the last drug intake—was considered to be below the
supposed threshold of virological response [5,6]. The dolute-
gravir daily dose was then increased to 50 mg twice a day with
more satisfying levels (peak level measured 2.5 h after intake,
6757 ng/mL; trough level, measured 12 h after intake, 3327 ng/
mL), according to the available information for adults. Dolute-
gravir plasma levels were checked monthly after the addition of
etravirine and darunavir/ritonavir. Peak levels of approximately
6000 ng/mL and trough levels between 2500 and 3000 ng/mL
were systematically observed.
Despite excellent efﬁcacy and tolerability in adults, dolute-
gravir use in children is poorly documented [7–9]. Indeed, the
drug is approved for adolescents, but not for children in the age
range of our patient. In the IMPAACT study (children ART-
experienced, II naive), 70% of adolescents (12 to <18 years
old) achieved HIV RNA values <50 copies/mL [10]. Results are
pending for the other age groups. The dolutegravir daily dose in
children still has to be deﬁned. In the IMPAACT study, the
administration of 1 mg/kg once daily achieved dolutegravir
levels comparable to those achieved with 50 mg once a day in
adults [10]. The study used 35 mg once a day for patients be-
tween 30 and 39 kg and 50 mg once a day for patients weighing
40 kg.
To our knowledge, the use of dolutegravir in treatment-
experienced children with raltegravir-resistant or elvitegravir-
resistant HIV infection has not been documented. With its
higher genetic barrier, dolutegravir maintains an activity in the
presence of some raltegravir- and elvitegravir-associated mu-
tations, including N155H [3]. The results of the VIKING study
showed a better viral response with twice-daily dosing in
treatment-experienced adults with RAL-resistant HIV infection
[11]. These data were an additional incentive to treat our 56-kgNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on b
This is an open access artipatient with a double dose of dolutegravir (50 mg twice daily).
Dolutegravir is known to be highly bound (98.9%) to human
plasma proteins [12]. Distribution does not appear to be
affected in the context of obesity, but literature is lacking. A
decrease in dolutegravir plasma levels after etravirine exposure
is well known. However, it has been demonstrated that this can
be counteracted by adding a boosted protease inhibitor (lopi-
navir/ritonavir or darunavir/ritonavir), presumably via inhibition
of CYP3A [4]. In our patient, the etravirine effect was coun-
terbalanced by darunavir/ritonavir with similar minimal dolu-
tegravir levels before and after the addition of both drugs. This
level has remained stable over the last 3 months. Although
dolutegravir was probably the most active drug in the antire-
troviral regimen, its individual weight in the combined therapy
cannot be established.
Importantly, the potential side-effects of this complex
regimen, which contains eight different drugs, require close
monitoring for drug toxicity. Although the regimens now in
use for naive patients are extremely well tolerated and can be
monitored even up to every 6 months, complex regimens
require very frequent assessment of liver and kidney func-
tions, haematological parameters, and adherence (monitoring
of pill number and drug levels, when available). In our case,
this has been performed every 30 to 60 days. Despite MDR,
our patient’s strain appears to have a high capacity for
replication, as shown by the high viral load observed when
treatment was stopped and the rapid decrease of CD4 cells.
In this context, the risk of toxicity was lower than the risk of
an unsuccessful regimen and the risk of development of
resistance to dolutegravir. Although it is controversial, we
decided to maintain enfuvirtide treatment until obtaining
undetectable viraemia, despite resistance, for a possible ac-
tion on viral ﬁtness [2,13].
To our knowledge, the use of high-dose dolutegravir in the
context of virological failure in a child has never been docu-
mented. Our case provides information on the use of dolute-
gravir in a child in the particular setting of an MDR HIV strain,
weight issues, a complex regimen and multiple drug–drug in-
teractions. In our case, dolutegravir has demonstrated efﬁcacy
and safety and the addition of darunavir/ritonavir counter-
balanced the negative effect of etravirine on dolutegravir plasma
levels. Close monitoring and a multidisciplinary approach are
recommended for an optimal management of these challenging
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